These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 38048417)

  • 1. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN).
    Sood V; Alam S; Nagral A; Srivastava A; Deshmukh A; Bavdekar A; Acharyya BC; Geetha SM; Gupte G; Bhatia I; Tiwari K; Bharadia L; Sathiyasekaran M; Kaur P; Khanna R; Shrivastava R; Poyekar S; Pandey S; Ramakrishna SH; Kinjawadekar U; Borkar V; Sivaramakrishnan VM; Kohli R; Matthai J; Dhawan A
    Indian Pediatr; 2024 Oct; 61(10):919-934. PubMed ID: 39297398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
    Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
    Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight/Obesity: A Systematic Review and Meta-Analysis.
    Dobbie LJ; Burgess J; Hamid A; Nevitt SJ; Hydes TJ; Alam U; Cuthbertson DJ
    Nutrients; 2024 Apr; 16(7):. PubMed ID: 38613063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
    van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
    Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.
    Cotrim HP; Parise ER; Figueiredo-Mendes C; Galizzi-Filho J; Porta G; Oliveira CP
    Arq Gastroenterol; 2016; 53(2):118-22. PubMed ID: 27305420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
    Halpern B; Mancini MC; van de Sande-Lee S; Miranda PAC
    Arch Endocrinol Metab; 2023 Aug; 67(4):e230174. PubMed ID: 37585688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.
    Beygi M; Ahi S; Zolghadri S; Stanek A
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease.
    Schwimmer JB; Newton KP; Awai HI; Choi LJ; Garcia MA; Ellis LL; Vanderwall K; Fontanesi J
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1267-77. PubMed ID: 24117728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
    Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE - ASSESSMENT OF PATIENTS WITH OBESITY AND METABOLIC SYNDROME - GUIDELINE FROM THE BRAZILIAN SOCIETY OF BARIATRIC AND METABOLIC SURGERY.
    Halamy Pereira L; Barros F; Andrade TG; Oliveira Neto AA; Nogueira CAV; Valezi AC
    Arq Bras Cir Dig; 2024; 37():e1821. PubMed ID: 39230102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease.
    van Dijk AM; de Vries M; El-Morabit F; Bac ST; Mundt MW; van der Schuit LE; Hirdes MMC; Kara M; de Bruijne J; van Meer S; Kaasjager HAH; de Valk HW; Vleggaar FP; van Erpecum KJ
    Intern Emerg Med; 2023 Nov; 18(8):2271-2280. PubMed ID: 37700180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.